Epitopoietic Research

ERC is a Belgian clinical-stage biotech pioneering a unique, patented cell-based immunotherapy for solid tumors, with a primary focus on recurrent glioblastoma (GBM). Its lead vaccine, Gliovac/ERC1671, combines autologous and allogeneic tumor cells to stimulate a potent anti-cancer immune response and has shown promising survival extensions in compassionate use. While advancing its GBM program through clinical trials, the company is also leveraging its platform to develop vaccines for viral infections, though it faces challenges typical of early-stage biotechs, including clinical validation and funding.

Patented cell-based immunotherapy platform using a combination of autologous and allogeneic whole tumor cells and lysates to stimulate a multi-antigenic immune response against cancer.

ERC competes in the competitive glioblastoma treatment landscape, which includes standard chemotherapies (temozolomide), tumor-treating fields (Optune), and a growing pipeline of investigational immunotherapies (e.g., cancer vaccines, CAR-T therapies) from both large pharma and biotech firms. Its unique autologous/allogeneic cell vaccine approach differentiates it, but it must prove superior efficacy against these evolving standards of care and novel modalities.